Virios Therapeutics, Inc.
VIRI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,531 | $2 | $8 | $11 |
| G&A Expenses | $8,696 | $4 | $4 | $5 |
| SG&A Expenses | $8,696 | $4 | $4 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12,227 | $5 | $12 | $16 |
| Operating Income | -$12,227 | -$5 | -$12 | -$16 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$123 | $0 | $0 | -$0 |
| Pre-Tax Income | -$12,350 | -$5 | -$12 | -$16 |
| Tax Expense | $1 | $0 | -$0 | $0 |
| Net Income | -$12,864 | -$5 | -$12 | -$16 |
| % Margin | – | – | – | – |
| EPS | -12.52 | -0.28 | -1.1 | -1.92 |
| % Growth | -4,371.4% | 74.5% | 42.7% | – |
| EPS Diluted | -12.52 | -0.28 | -1.1 | -1.92 |
| Weighted Avg Shares Out | 1,028 | 19 | 11 | 8 |
| Weighted Avg Shares Out Dil | 1,028 | 19 | 11 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $92 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $5 | $12 | $16 |
| EBITDA | -$12,227 | $0 | -$12 | -$16 |
| % Margin | – | – | – | – |